Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KappaMab - HaemaLogiX

Drug Profile

KappaMab - HaemaLogiX

Alternative Names: IST-1097; MDX-1097; MDX-1097 (kappa)

Latest Information Update: 03 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immune System Therapeutics; Medarex
  • Developer HaemaLogiX
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Multiple myeloma

Most Recent Events

  • 14 Aug 2019 KappaMab is still in phase IIb trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Australia (ACTRN12616001164482p)
  • 13 Jun 2019 Efficacy and adverse event data from a phase IIa trial in Multiple myeloma released by HaemaLogiX
  • 13 Jun 2019 Efficacy and adverse event data from a phase IIb trial in Multiple myeloma released by HaemaLogiX
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top